Gilead Strengthens Immunology Pipeline with Up to $1.7B Ouro Medicines Deal

Foster City, CA, March 23, 2026 (Business Wire) -- Gilead Sciences has entered an agreement to acquire Ouro Medicines in a deal valued at up to $1.7 billion. The acquisition is designed to enhance its development of T-cell engager therapies targeting autoimmune diseases. Integrating Ouro’s platform is expected to accelerate progress on novel immunology treatments.

Read full article here.